Signal Explorer
10-K · 10-Q · 8-K · last 6 months · ← back to feed
Cyclerion Therapeutics, Inc.
CYCN
Other
Cash Flow Statement Investing Activities
Executive Educational Background Disclosure
Director Officer Indemnification Provision
Lease Rou Incremental Borrowing Rate Disclosure
Audit Committee Independence Certification
Net Loss Reported
Code Of Conduct Adoption Disclosure
Effective Tax Rate Reconciliation
New York Jurisdiction Clause
Employee Director Compensation Waiver
Reverse Stock Split Effected
Fcpa Compliance Representation
Diversity Equity Inclusion Commitment
Nyse Listing Disclosure
Core
Management Exodus
Other
Auditor Appointment Ratification
Reverse Stock Split Effected
Say On Pay Vote Result Disclosed
Equity Plan Board Approval Conditional On Shareholder Vote
Quorum Presence Disclosed
Adjournment Proposal Voting Requirement
Nyse Listing Disclosure
Other
Net Loss Reported
Liquidity Position Snapshot Disclosed
Cash Flow Statement Investing Activities
Fair Value Hierarchy Reconciliation Disclosed
Stock Option Grant Disclosed
Financing Activities Cash Flow Disclosure
Institutional Investment
Shares Outstanding Disclosure
Ipo Or Capital Raising Completion
Personnel Cost Decrease Disclosure
Interest Income Year Over Year Comparison
Burn Rate Controlled
Convertible Debt Conversion
Rsu Psu Vesting Schedule Disclosed
Other
Net Loss Reported
Capital Raising Uncertainty Disclosed
Fair Value Hierarchy Reconciliation Disclosed
Cash Flow Statement Investing Activities
Liquidity Position Snapshot Disclosed
Ipo Or Capital Raising Completion
Institutional Investment
Financing Activities Cash Flow Disclosure
Use Of Proceeds Disclosure
Shares Outstanding Disclosure
Interim Data Positive
Reverse Stock Split Effected
Fast Track Designation Received
Core
Lead Asset Progress
Indication Expansion
Other
Earnings Call Qa Segment
Corporate Organization And Standing Representation
Reverse Stock Split Effected
Fcpa Compliance Representation
Merger Subsidiary Creation
Earnings Call Replay Details
Share Withholding Tax Settlement
Merger Proxy Statement Disclosure
Successor Agent Appointment Provision
Corporate Authority Representation
Market Price Definition
Amendment Modification Waiver Clause
Registration Rights Piggyback Provision
Non Assignment Clause
Core
Clinical Trial Result
Other
Capital Raising Uncertainty Disclosed
Fcpa Compliance Representation
Net Loss Reported
Patent Family Portfolio Disclosure
Confidential Information Return Obligation
New York Jurisdiction Clause
Institutional Investment
Form S3 Shelf Registration Disclosure
Shareholder Dilution Warning
Nasdaq Minimum Bid Price Delisting Notice
Cybersecurity Risk Management Program Disclosure
Diversity Equity Inclusion Commitment
Nyse Listing Disclosure
Termination For Material Breach Clause
Core
Clinical Trial Result